Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of ca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/14/4478 |
| _version_ | 1797444885417033728 |
|---|---|
| author | Sijongesonke Peter Sibusiso Alven Rejoice Bethusile Maseko Blessing Atim Aderibigbe |
| author_facet | Sijongesonke Peter Sibusiso Alven Rejoice Bethusile Maseko Blessing Atim Aderibigbe |
| author_sort | Sijongesonke Peter |
| collection | DOAJ |
| description | The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca<sup>2+</sup>, and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects. |
| first_indexed | 2024-03-09T13:17:55Z |
| format | Article |
| id | doaj.art-dea593815f5746f49be554437f8148ff |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T13:17:55Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-dea593815f5746f49be554437f8148ff2023-11-30T21:33:35ZengMDPI AGMolecules1420-30492022-07-012714447810.3390/molecules27144478Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A ReviewSijongesonke Peter0Sibusiso Alven1Rejoice Bethusile Maseko2Blessing Atim Aderibigbe3Department of Chemistry, University of Fort Hare, Alice 5700, South AfricaDepartment of Chemistry, University of Fort Hare, Alice 5700, South AfricaDepartment of Chemistry, School of Science and Technology, Sefako Makgatho Health Sciences University, Ga-Rankuwa 0208, South AfricaDepartment of Chemistry, University of Fort Hare, Alice 5700, South AfricaThe scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca<sup>2+</sup>, and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects.https://www.mdpi.com/1420-3049/27/14/4478cancerdoxorubicinhybrid compoundsdrug resistancedrug toxicitychemotherapeutic drugs |
| spellingShingle | Sijongesonke Peter Sibusiso Alven Rejoice Bethusile Maseko Blessing Atim Aderibigbe Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review Molecules cancer doxorubicin hybrid compounds drug resistance drug toxicity chemotherapeutic drugs |
| title | Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review |
| title_full | Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review |
| title_fullStr | Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review |
| title_full_unstemmed | Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review |
| title_short | Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review |
| title_sort | doxorubicin based hybrid compounds as potential anticancer agents a review |
| topic | cancer doxorubicin hybrid compounds drug resistance drug toxicity chemotherapeutic drugs |
| url | https://www.mdpi.com/1420-3049/27/14/4478 |
| work_keys_str_mv | AT sijongesonkepeter doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview AT sibusisoalven doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview AT rejoicebethusilemaseko doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview AT blessingatimaderibigbe doxorubicinbasedhybridcompoundsaspotentialanticanceragentsareview |